Try a new search

Format these results:

Searched for:

school:SOM

Department/Unit:Cell Biology

Total Results:

14210


A bioactive compliant vascular graft modulates macrophage polarization and maintains patency with robust vascular remodeling

Stahl, Alexander; Hao, Dake; Barrera, Janos; Henn, Dominic; Lin, Sien; Moeinzadeh, Seyedsina; Kim, Sungwoo; Maloney, William; Gurtner, Geoffrey; Wang, Aijun; Yang, Yunzhi Peter
Conventional synthetic vascular grafts are associated with significant failure rates due to their mismatched mechanical properties with the native vessel and poor regenerative potential. Though different tissue engineering approaches have been used to improve the biocompatibility of synthetic vascular grafts, it is still crucial to develop a new generation of synthetic grafts that can match the dynamics of native vessel and direct the host response to achieve robust vascular regeneration. The size of pores within implanted biomaterials has shown significant effects on macrophage polarization, which has been further confirmed as necessary for efficient vascular formation and remodeling. Here, we developed biodegradable, autoclavable synthetic vascular grafts from a new polyurethane elastomer and tailored the grafts' interconnected pore sizes to promote macrophage populations with a pro-regenerative phenotype and improve vascular regeneration and patency rate. The synthetic vascular grafts showed similar mechanical properties to native blood vessels, encouraged macrophage populations with varying M2 to M1 phenotypic expression, and maintained patency and vascular regeneration in a one-month rat carotid interposition model and in a four-month rat aortic interposition model. This innovative bioactive synthetic vascular graft holds promise to treat clinical vascular diseases.
PMCID:9034314
PMID: 35510174
ISSN: 2452-199x
CID: 5678182

The standardized exploration of the radial nerve during humeral shaft fixation reduces the incidence of iatrogenic palsy

Belayneh, Rebekah; Littlefield, Connor P; Konda, Sanjit R; Broder, Kari; Kugelman, David N; Leucht, Philipp; Egol, Kenneth A
BACKGROUND:The purpose of this study is to determine if a standardized protocol for radial nerve handling during humeral shaft repair reduces the incidence of iatrogenic nerve palsy post operatively. METHODS:Seventy-three patients were identified who underwent acute or reconstructive humeral shaft repair with radial nerve exploration as part of the primary procedure for either humeral shaft fracture or nonunion. All patients exhibited intact radial nerve function pre-operatively. A retrospective chart review and analysis identified patients who developed a secondary radial nerve palsy post-operatively. In each case, the radial nerve was identified and mobilized for protection, regardless of whether the implant necessitated the extensile exposure. RESULTS:Fractures were classified according to AO/OTA guidelines and included 23 Type 12A, 11 Type 12B, and 3 Type 12C. Eight patients had periprosthetic fractures and 28 fractures could not be classified. All patients in the cohort were fixed with locking plates. Surgery was indicated for 36 patients with humeral nonunions and 37 patients with acute humeral shaft fractures. Of the 73 patients, 2 (2.7%) developed radial nerve palsy following surgery, one from the posterior approach and one from the anterolateral approach. Both patients exhibited complete recovery of radial nerve function by 6-month follow-up. No significant differences (p > 0.05) were found in any demographic or surgical details between those with and without radial nerve injury. CONCLUSIONS:Nerve exploration identification and protection leads to a low incidence of transient radial nerve palsy compared to the rate reported in the current literature (2.7% compared to 6-24%). Thus, radial nerve exploration and mobilization should be considered when approaching the humeral shaft for acute fracture and nonunion repairs. LEVEL OF EVIDENCE/METHODS:Level III.
PMID: 34191088
ISSN: 1434-3916
CID: 4947592

Posttranscriptional regulation of neurofilament proteins and tau in health and disease

Yuan, Aidong; Nixon, Ralph A
Neurofilament and tau proteins are neuron-specific cytoskeletal proteins that are enriched in axons, regulated by many of the same protein kinases, interact physically, and are the principal constituents of neurofibrillary lesions in major adult-onset dementias. Both proteins share functions related to the modulation of stability and functions of the microtubule network in axons, axonal transport and scaffolding of organelles, long-term synaptic potentiation, and learning and memory. Expression of these proteins is regulated not only at the transcriptional level but also through posttranscriptional control of pre-mRNA splicing, mRNA stability, transport, localization, local translation and degradation. Current evidence suggests that posttranscriptional determinants of their levels are usually regulated by RNA-binding proteins and microRNAs primarily through 3'-untranslated regions of neurofilament and tau mRNAs. Dysregulations of neurofilament and tau expression caused by mutations or pathologies of RNA-binding proteins such as TDP43, FUS and microRNAs are increasingly recognized in association with varied neurological disorders. In this review, we summarize the current understanding of posttranscriptional control of neurofilament and tau by examining the posttranscriptional regulation of neurofilament and tau by RNA-binding proteins and microRNAs implicated in health and diseases.
PMID: 36441047
ISSN: 1873-2747
CID: 5373862

Overall survival (OS) in patients treated with adjuvant nivolumab (NIVO): Comparison of data from the phase 3 randomized Checkmate 238 (CM238) trial with real world (RW) data [Meeting Abstract]

Moser, J; Bhatia, S; Amin, A; Pavlick, A C; Betts, K; Du, E; Poretta, T; Moshyk, A; Sakkal, L A; Palaia, J; Lobo, M; Benito, M P; Kadakia, R; Chen, Y; Xu, C; Yin, L; Sundar, M; Weber, J
In CM238, 76% of patients (pts) with high-risk resected melanoma (MEL) treated with adjuvant NIVO were alive at 5 years, but there is limited RW data to validate these findings in a similar patient population. This study compared the OS of pts treated with adjuvant NIVO in CM238 vs. RW pts. Pts with stage III resected MEL (AJCC 8th edition) who received adjuvant NIVO were selected from CM238 and the nationwide Flatiron Health electronic health record-derived de-identified database (the RW cohort). Pts in the RW cohort were required to meet the eligibility criteria in CM238 where possible. OS/real-world OS (rwOS) were evaluated using Kaplan-Meier methods and compared using Cox proportional hazards models after adjusting for key prognostic baseline variables (age, sex, race, disease stage, time from surgical resection to index date, ECOG, and comorbidities) between the two cohorts. In the RW cohort, 492 pts with resected stage III MEL received adjuvant NIVO and 320 pts met the eligibility criteria of CM238. Compared with pts in the CM238 cohort, pts in the RW cohort were older (median: 64 vs. 56 years), heavier (91 vs. 82 kg), had a higher proportion of diabetes (9% vs. 6%) and ECOG PS 1 (17% vs. 10%), and had slightly more stage IIIA (4% vs. 1%), less stage IIIB (29% vs. 32%), and similar stage IIIC (63% vs. 63%) and stage IIID (4% vs. 5%). Before adjustment, pts in the RW cohort had a higher risk of mortality compared with pts in the CM238 cohort (HR: 1.46; 95% CI, 1.00 to 2.13; p < 0.05). After adjusting for differences in key patient characteristics, OS was similar between the two cohorts (HR: 1.12; 95% CI, 0.68 to 1.84, p = 0.66). In conclusion, pts with stage III resected MEL treated with adjuvant NIVO in the RW setting had OS similar to those in CM238 after adjusting for key prognostic factors
EMBASE:640045833
ISSN: 1755-148x
CID: 5511232

Correction: SAR user guide to the rectal MR synoptic report (primary staging)

Kassam, Z; Lang, R; Bates, D D B; Chang, K J; Fraum, T J; Friedman, K A; Golia Pernicka, J S; Gollub, M J; Harisinghani, M; Khatri, G; Lall, C; Lee, S; Magnetta, M; Nougaret, S; Paspulati, R M; Paroder, V; Shaish, H; Kim, D H; ,
PMID: 36114288
ISSN: 2366-0058
CID: 6022702

Cocaine perturbs mitovesicle biology in the brain

D'Acunzo, Pasquale; Ungania, Jonathan M; Kim, Yohan; Barreto, Bryana R; DeRosa, Steven; Pawlik, Monika; Canals-Baker, Stefanie; Erdjument-Bromage, Hediye; Hashim, Audrey; Goulbourne, Chris N; Neubert, Thomas A; Saito, Mariko; Sershen, Henry; Levy, Efrat
Cocaine, an addictive psychostimulant, has a broad mechanism of action, including the induction of a wide range of alterations in brain metabolism and mitochondrial homeostasis. Our group recently identified a subpopulation of non-microvesicular, non-exosomal extracellular vesicles of mitochondrial origin (mitovesicles) and developed a method to isolate mitovesicles from brain parenchyma. We hypothesised that the generation and secretion of mitovesicles is affected by mitochondrial abnormalities induced by chronic cocaine exposure. Mitovesicles from the brain extracellular space of cocaine-administered mice were enlarged and more numerous when compared to controls, supporting a model in which mitovesicle biogenesis is enhanced in the presence of mitochondrial alterations. This interrelationship was confirmed in vitro. Moreover, cocaine affected mitovesicle protein composition, causing a functional alteration in mitovesicle ATP production capacity. These data suggest that mitovesicles are previously unidentified players in the biology of cocaine addiction and that target therapies to fine-tune brain mitovesicle functionality may be beneficial to mitigate the effects of chronic cocaine exposure.
PMCID:9871795
PMID: 36691887
ISSN: 2001-3078
CID: 5426532

Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer

Zhang, Shirong; Wang, Wenxian; Xu, Chunwei; Zhang, Yongchang; Cai, Xiuyu; Wang, Qian; Song, Zhengbo; Li, Ziming; Yu, Jinpu; Zhong, Wenzhao; Wang, Zhijie; Liu, Jingjing; Liu, Anwen; Li, Wen; Zhan, Ping; Liu, Hongbing; Lv, Tangfeng; Miao, Liyun; Min, Lingfeng; Lin, Gen; Huang, Long; Yuan, Jingping; Jiang, Zhansheng; Pu, Xingxiang; Rao, Chuangzhou; Lv, Dongqing; Yu, Zongyang; Li, Xiaoyan; Tang, Chuanhao; Zhou, Chengzhi; Zhang, Junping; Guo, Hui; Chu, Qian; Meng, Rui; Liu, Xuewen; Wu, Jingxun; Zhou, Jin; Zhu, Zhengfei; Pan, Weiwei; Dong, Xiaowei; Pang, Fei; Wang, Kai; Yao, Chao; Lin, Guomin; Li, Site; Yang, Zhi; Luo, Jiancheng; Jia, Hongtao; Nie, Xiuqing; Wang, Liping; Zhu, Youcai; Hu, Xiao; Xie, Yanru; Lin, Xinqing; Cai, Jing; Xia, Yang; Feng, Huijing; Wang, Lin; Du, Yingying; Yao, Wang; Shi, Xuefei; Niu, Xiaomin; Yuan, Dongmei; Yao, Yanwen; Kang, Jing; Zhang, Jiatao; Zhang, Chao; Gao, Wenbin; Huang, Jianhui; Zhang, Yinbin; Sun, Pingli; Wang, Hong; Ye, Mingxiang; Wang, Dong; Wang, Zhaofeng; Wan, Bing; Lv, Donglai; Yu, Genhua; Shi, Lin; Xia, Yuanli; Gao, Feng; Zhang, Xiaochen; Xu, Tao; Zhou, Wei; Wang, Haixia; Liu, Zhefeng; Yang, Nong; Wu, Lin; Wang, Qiming; Wang, Guansong; Hong, Zhuan; Wang, Jiandong; Fang, Meiyu; Fang, Yong; Zhang, Yiping; Song, Yong; Ma, Shenglin; Fang, Wenfeng; Lu, Yuanzhi
Human epidermal growth factor receptor 2 (HER2) possesses tyrosine kinase activity and participates in cell growth, differentiation and migration, and survival. Its alterations, mainly including mutations, amplifications, and overexpression are associated with poor prognosis and are one of the major drivers in non-small cell lung cancer (NSCLC). Several clinical trials had been investigating on the treatments of HER2-altered NSCLC, including conventional chemotherapy, programmed death 1 (PD-1) inhibitors, tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs), however, the results were either disappointing or encouraging, but inconsistent. Trastuzumab deruxtecan (T-DXd) was recently approved by the Food and Drug Administration as the first targeted agent for treating HER2-mutant NSCLC. Effective screening of patients is the key to the clinical application of HER2-targeted agents such as TKIs and ADCs. Various testing methods are nowadays available, including polymerase chain reaction (PCR), next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), etc. Each method has its pros and cons and should be reasonably assigned to appropriate patients for diagnosis and guiding treatment decisions. To help standardize the clinical workflow, our expert group reached a consensus on the clinical management of HER2-altered NSCLC, focusing on the diagnosis and treatment strategies.
PMCID:9807451
PMID: 36444143
ISSN: 1759-7714
CID: 5414362

Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1

Thomas, Jonathan F.; Valencia-Sanchez, Marco Igor; Tamburri, Simone; Gloor, Susan L.; Rustichelli, Samantha; Godinez-Lopez, Victoria; De Ioannes, Pablo; Lee, Rachel; Abini-Agbomson, Stephen; Gretarsson, Kristjan; Burg, Jonathan M.; Hickman, Allison R.; Sun, Lu; Gopinath, Saarang; Taylor, Hailey F.; Sun, Zu-Wen; Ezell, Ryan J.; Vaidya, Anup; Meiners, Matthew J.; Cheek, Marcus A.; Rice, William J.; Svetlov, Vladimir; Nudler, Evgeny; Lu, Chao; Keogh, Michael-Christopher; Pasini, Diego; Armache, Karim-Jean
ISI:001045489300011
ISSN: 2375-2548
CID: 5852362

Methods for Single Cell Transcriptomic Analysis of Adipose Tissue

Shamsi, Farnaz
The development of single cell approaches has facilitated the investigation of cellular heterogeneity and cell type-specific gene expression in complex tissues. Adipose tissue depots contain lipid storing adipocytes as well as a diverse array of cell types that form the adipocyte niche and regulate adipose tissue function. Here, I describe two protocols for the isolation of single cells and nuclei from white and brown adipose tissue. Additionally, I provide a detailed workflow for isolation of cell type- or lineage-specific single nuclei using nuclear tagging and translating ribosome affinity purification (NuTRAP) mouse models.
PMID: 37076686
ISSN: 1940-6029
CID: 5464542

Confronting the loss of trophic support

Hu, Hui-Lan; Khatri, Latika; Santacruz, Marilyn; Church, Emily; Moore, Christopher; Huang, Tony T; Chao, Moses V
Classic experiments with peripheral sympathetic neurons established an absolute dependence upon NGF for survival. A forgotten problem is how these neurons become resistant to deprivation of trophic factors. The question is whether and how neurons can survive in the absence of trophic support. However, the mechanism is not understood how neurons switch their phenotype to lose their dependence on trophic factors, such as NGF and BDNF. Here, we approach the problem by considering the requirements for trophic support of peripheral sympathetic neurons and hippocampal neurons from the central nervous system. We developed cellular assays to assess trophic factor dependency for sympathetic and hippocampal neurons and identified factors that rescue neurons in the absence of trophic support. They include enhanced expression of a subunit of the NGF receptor (Neurotrophin Receptor Homolog, NRH) in sympathetic neurons and an increase of the expression of the glucocorticoid receptor in hippocampal neurons. The results are significant since levels and activity of trophic factors are responsible for many neuropsychiatric conditions. Resistance of neurons to trophic factor deprivation may be relevant to the underlying basis of longevity, as well as an important element in preventing neurodegeneration.
PMCID:10338843
PMID: 37456526
ISSN: 1662-5099
CID: 5535402